Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kohn

Showing results (301-310 of 369) with videos related to

Pageof 37
Sort By:
Cancer Research|February 1, 1996
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancersE C Kohn, E Reed, G Sarosy, et al.
Cancer|June 15, 2007
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profilingEdwin M Posadas, Virginia Kwitkowski, Herbert L Kotz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2Christina M Annunziata, Amanda J Walker, Lori Minasian, et al.
Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.
Gynecologic Oncology|August 1, 1996
A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancerE C Kohn, G A Sarosy, P Davis, et al.
Journal of the National Cancer Institute|March 15, 2014
Better therapeutic trials in ovarian cancerMichael A Bookman, C Blake Gilks, Elise C Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndromeE C Kohn, R G Steis, E A Sausville, et al.
Virchows Archiv : an International Journal of Pathology|April 14, 2006
Comparative study of T84 and T84SF human colon carcinoma cells: in vitro and in vivo ultrastructural and functional characterization of cell culture and metastasisRiccardo Alessandro, Maria Antonietta Di Bella, Anna Maria Flugy, et al.
British Journal of Cancer|May 18, 2001
Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformationF G Perabo, S Kamp, D Schmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancerMahrukh M Hussain, Herbert Kotz, Lori Minasian, et al.
Pageof 37

Showing results (301-310 of 369) with videos related to

Sort By:
Pageof 37
Cancer Research|February 1, 1996
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancersE C Kohn, E Reed, G Sarosy, et al.
Cancer|June 15, 2007
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profilingEdwin M Posadas, Virginia Kwitkowski, Herbert L Kotz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2Christina M Annunziata, Amanda J Walker, Lori Minasian, et al.
Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.
Gynecologic Oncology|August 1, 1996
A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancerE C Kohn, G A Sarosy, P Davis, et al.
Journal of the National Cancer Institute|March 15, 2014
Better therapeutic trials in ovarian cancerMichael A Bookman, C Blake Gilks, Elise C Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndromeE C Kohn, R G Steis, E A Sausville, et al.
Virchows Archiv : an International Journal of Pathology|April 14, 2006
Comparative study of T84 and T84SF human colon carcinoma cells: in vitro and in vivo ultrastructural and functional characterization of cell culture and metastasisRiccardo Alessandro, Maria Antonietta Di Bella, Anna Maria Flugy, et al.
British Journal of Cancer|May 18, 2001
Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformationF G Perabo, S Kamp, D Schmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancerMahrukh M Hussain, Herbert Kotz, Lori Minasian, et al.
Pageof 37